StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96−0.10 (-1.24%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

Novavax operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Novavax's operating cash flow for the twelve months ending Jun 30, 2026 was -$36.90M. For fiscal 2025 it was -$244.64M. The highest annual figure on record is $322.95M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$244.64M–
FY2024Dec 31, 2024-$87.26M–
FY2023Dec 31, 2023-$713.97M–
FY2022Dec 31, 2022-$415.94M-228.8%
FY2021Dec 31, 2021$322.95M–
FY2020Dec 31, 2020-$42.54M–
FY2019Dec 31, 2019-$136.62M–
FY2018Dec 31, 2018-$184.83M–
FY2017Dec 31, 2017-$144.48M–
FY2016Dec 31, 2016-$258.77M–
FY2015Dec 31, 2015-$126.09M–
FY2014Dec 31, 2014-$67.01M–
FY2013Dec 31, 2013-$45.36M–
FY2012Dec 31, 2012-$18.23M–
FY2011Dec 31, 2011-$23.63M–
FY2010Dec 31, 2010-$32.85M–
FY2009Dec 31, 2009-$32.83M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$72.81M–
Q1 FY2026Mar 31, 2026-$32.42M–
Q4 FY2025Dec 31, 2025-$39.48M–
Q3 FY2025Sep 30, 2025$107.80M–
Q2 FY2025Jun 30, 2025-$127.46M-140.6%
Q1 FY2025Mar 31, 2025-$185.50M–
Q4 FY2024Dec 31, 2024-$173.16M–
Q3 FY2024Sep 30, 2024-$144.81M–
Q2 FY2024Jun 30, 2024$314.27M–
Q1 FY2024Mar 31, 2024-$83.56M–
Q4 FY2023Dec 31, 2023-$176.78M–
Q3 FY2023Sep 30, 2023-$39.66M–
Q2 FY2023Jun 30, 2023-$171.94M–
Q1 FY2023Mar 31, 2023-$325.59M–
Q4 FY2022Dec 31, 2022-$117.82M–
Q3 FY2022Sep 30, 2022-$38.71M–
Q2 FY2022Jun 30, 2022-$170.90M-218.3%
Q1 FY2022Mar 31, 2022-$88.51M-113.3%
Q4 FY2021Dec 31, 2021-$342.41M–
Q3 FY2021Sep 30, 2021-$142.14M–
Q2 FY2021Jun 30, 2021$144.41M+24.9%
Q1 FY2021Mar 31, 2021$663.09M–
Q4 FY2020Dec 31, 2020-$128.57M–
Q3 FY2020Sep 30, 2020-$6.50M–
Q2 FY2020Jun 30, 2020$115.63M–
Q1 FY2020Mar 31, 2020-$23.11M–
Q4 FY2019Dec 31, 2019-$23.74M–
Q3 FY2019Sep 30, 2019-$32.26M–
Q2 FY2019Jun 30, 2019-$30.01M–
Q1 FY2019Mar 31, 2019-$50.61M–
Q4 FY2018Dec 31, 2018-$45.27M–
Q3 FY2018Sep 30, 2018-$33.51M–
Q2 FY2018Jun 30, 2018-$39.97M–
Q1 FY2018Mar 31, 2018-$66.08M–
Q4 FY2017Dec 31, 2017-$43.40M–
Q3 FY2017Sep 30, 2017-$44.18M–
Q2 FY2017Jun 30, 2017-$12.40M–
Q1 FY2017Mar 31, 2017-$44.50M–
Q4 FY2016Dec 31, 2016-$64.55M–
Q3 FY2016Sep 30, 2016-$62.36M–

More Novavax figures

See a number that looks wrong?